Merus N.V. (MRUS)
NASDAQ: MRUS · IEX Real-Time Price · USD
47.93
+0.90 (1.92%)
May 2, 2024, 2:39 PM EDT - Market open
Merus Revenue
In the year 2023, Merus had annual revenue of $43.95M with 5.68% growth. Revenue in the quarter ending December 31, 2023 was $8.94M, a -16.19% decrease year-over-year.
Revenue (ttm)
$43.95M
Revenue Growth
+5.68%
P/S Ratio
63.22
Revenue / Employee
$191,908
Employees
229
Market Cap
2.78B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | 31.13M | -7.25M | -18.88% |
Dec 31, 2018 | 38.38M | 14.27M | 59.20% |
Dec 31, 2017 | 24.11M | 21.35M | 773.11% |
Dec 31, 2016 | 2.76M | 665.50K | 31.76% |
Dec 31, 2015 | 2.10M | 662.20K | 46.20% |
Dec 31, 2014 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
QuidelOrtho | 3.00B |
Premier | 1.32B |
Indivior | 1.12B |
Neogen | 929.24M |
PTC Therapeutics | 927.56M |
MorphoSys AG | 264.75M |
PROCEPT BioRobotics | 136.19M |
Celldex Therapeutics | 6.88M |
MRUS News
- 8 days ago - Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 24 days ago - Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers - Business Wire
- 2 months ago - Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update - GlobeNewsWire
- 3 months ago - Merus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023 - GlobeNewsWire
- 5 months ago - Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023 - GlobeNewsWire
- 6 months ago - Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update - GlobeNewsWire